Nanalysis Boosts Private Placement with New Tranche, Securing $2.5 Million Funding

Nanalysis Upsizes Private Placement and Closes Initial Tranche

On December 23, 2025, Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1) announced a significant milestone in its financial strategy. The company successfully closed the first tranche of its non-brokered private placement, issuing a total of 16,526,283 units at $0.15 per unit, resulting in gross proceeds of approximately $2.5 million. The proceeds from this offering will primarily be directed towards reducing the company's existing debt, as previously communicated in a press release dated December 8, 2025.

In an exciting turn of events, due to high demand from investors, Nanalysis is increasing the total size of the private placement. The company has decided to offer an additional 23,333,333 units at the same price of $0.15 per unit, which could raise up to $3.5 million in aggregate gross proceeds. This upsize will also require approval from the TSX Venture Exchange and will further assist the company with its debt reduction initiatives and inventory acquisitions.

Each unit comprises one common share and half a warrant, with each full warrant allowing the holder to purchase an additional share at $0.20 anytime before the expiration date that will fall two years post-closing. Additionally, an acceleration clause is in place that enables the company to force the exercise of the warrants if shares trade at or above $0.30 for ten consecutive days.

The first tranche marks a significant step in Nanalysis’s efforts to strengthen its financial position and take advantage of growth opportunities. A cash commission of $1,500 was paid to Haywood Securities Inc. for assisting with the placement. It's important to note that all securities from this tranche are subject to a statutory hold period of four months and one day from the issuance date. Nanalysis anticipates completing more tranches, contingent on market conditions and regulatory approvals.

Interestingly, Sean Krakiwsky, a key insider of the company, participated in this offering by subscribing for $52,500 in units, amounting to 350,000 units. This investment is deemed a 'related party transaction' as classified under Multilateral Instrument 61-101. Nanalysis has confirmed it meets exemption requirements, stating the fair market value of Krakiwsky’s participation does not exceed 25% of the company's total market capitalization.

It’s essential to clarify that this news release does not act as an offer to sell securities, nor does it solicit any buys in jurisdictions where such actions could be considered illegal. The securities involved are not registered under the United States Securities Act of 1933, and will not be offered or sold in the U.S. unless compliant with registration or exemptions.

About Nanalysis Scientific Corp.

Nanalysis Scientific Corp. is a leader in developing portable Nuclear Magnetic Resonance (NMR) spectrometers, utilized in various industries such as pharmaceuticals, biotech, security, and academic research globally. The company also has a burgeoning services division responsible for maintaining both its own devices and third-party imaging equipment. This aspect of their business is bolstered by a $160 million long-term contract with the Canadian Air Transport Security Authority (CATSA), which includes maintaining security scanners at over 80 airports across Canada.

Forward-Looking Statements Disclaimer: This news release contains forward-looking statements, which may be recognized by terms such as